Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francis S Mah

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Journal of Refractive Surgery (Thorofare, N.J. : 1995)|June 25, 2021
Clarifying the Disease State of PresbyopiaFrancis S Mah
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 2, 2016
Effect on Gel Formation Time of Adding Topical Ophthalmic Medications to ReSure Sealant, an In Situ HydrogelFrancis S Mah
Current Opinion in Ophthalmology|July 3, 2004
Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infectionsFrancis S Mah
Ophthalmology Clinics of North America|April 10, 2003
New antibiotics for bacterial infectionsFrancis S Mah
Ophthalmology and Therapy|October 28, 2021
Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of BlepharokeratoconjunctivitisFrancis S Mah, Paul M Karpecki
Clinical Ophthalmology (Auckland, N.Z.)|March 10, 2011
Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitisJeremy B Wingard, Francis S Mah
Clinical Ophthalmology (Auckland, N.Z.)|May 17, 2011
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitisLorenzo J Cervantes, Francis S Mah
Ophthalmology|October 23, 2017
Inflammation in Dry Eye Disease: How Do We Break the Cycle?Michelle K Rhee, Francis S Mah
Clinical Ophthalmology (Auckland, N.Z.)|August 10, 2017
Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literatureMichelle K Rhee, Francis S Mah
Advances in Therapy|May 29, 2007
Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitisSteven S Rhee, Francis S Mah
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Journal of Refractive Surgery (Thorofare, N.J. : 1995)|June 25, 2021
Clarifying the Disease State of PresbyopiaFrancis S Mah
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 2, 2016
Effect on Gel Formation Time of Adding Topical Ophthalmic Medications to ReSure Sealant, an In Situ HydrogelFrancis S Mah
Current Opinion in Ophthalmology|July 3, 2004
Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infectionsFrancis S Mah
Ophthalmology Clinics of North America|April 10, 2003
New antibiotics for bacterial infectionsFrancis S Mah
Ophthalmology and Therapy|October 28, 2021
Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of BlepharokeratoconjunctivitisFrancis S Mah, Paul M Karpecki
Clinical Ophthalmology (Auckland, N.Z.)|March 10, 2011
Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitisJeremy B Wingard, Francis S Mah
Clinical Ophthalmology (Auckland, N.Z.)|May 17, 2011
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitisLorenzo J Cervantes, Francis S Mah
Ophthalmology|October 23, 2017
Inflammation in Dry Eye Disease: How Do We Break the Cycle?Michelle K Rhee, Francis S Mah
Clinical Ophthalmology (Auckland, N.Z.)|August 10, 2017
Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literatureMichelle K Rhee, Francis S Mah
Advances in Therapy|May 29, 2007
Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitisSteven S Rhee, Francis S Mah
Pageof 9